Fosaprepitant Injection, Powder, Lyophilized, For Solution
Product Images NDC 68001-675

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Fosaprepitant (NDC 68001-675). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Caton (Fosaprepitant for Injection 150 mg per vial)

This text appears to be a pharmaceutical product description. It provides details about a medication called Fosaprepitant, including its composition, reconstitution instructions, and cautionary information. The medication is in lyophilized powder form for intravenous use and needs to be reconstituted with 0.9% Sodium Chloride for Injection. It advises against using the medication with solutions containing divalent cations and specifies it is for single-dose use only. The product is manufactured in Telangana, India.*

FDA Label Image

Str (Fosaprepitant Structure)

FDA Label Image

Vial Label- Fosaprepitant For Injection 150mg Per Vial (Fosaprepitant Vial Label)

This text provides important information about storing a vial refrigerated at 2°C to 8°C (36°F to 46°F), as well as the stability of the reconstituted final drug solution at room temperature for 24 hours. It mentions the usual dosage and instructions for injecting the sterile lyophilized powder for intravenous use only after reconstitution and dilution. The product is manufactured by MSN Laboratories Private Limited in India for BluePoint Laboratories.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.